American pharmaceutical giant Johnson & Johnson announced on the 21st the results of a clinical trial that the effectiveness of preventing the aggravation of the new coronavirus vaccine, which is a single inoculation type, has increased by giving an additional inoculation. bottom.
Johnson & Johnson's new coronavirus vaccine was approved for emergency use by the US FDA = Food and Drug Administration in February, and has been inoculated more than 14.8 million times in the United States so far.
Although the prescribed number of vaccinations for this vaccine is one, clinical trials have been conducted to see if additional vaccinations will improve efficacy.
According to the results of a clinical trial released by the company on the 21st, the effectiveness of preventing moderate to severe symptoms was 75% when the second dose was given 8 weeks after the first dose.
The antibody level also increased 4 to 6 times compared to after the first inoculation.
In addition, when the second inoculation was given about 6 months after the first inoculation, the antibody level increased up to 12 times.
Johnson & Johnson plans to publish all data from clinical trials in the future.